基本信息:
- 专利标题： NOVEL TNFa STRUCTURE FOR USE IN THERAPY
- 申请号：US17013326 申请日：2020-09-04
- 公开(公告)号：US20210088530A1 公开(公告)日：2021-03-25
- 发明人： James Philip O'CONNELL , John Robert PORTER , Alastair LAWSON , Boris KROEPLIEN , Stephen Edward RAPECKI , Timothy John NORMAN , Graham John WARRELLOW , Tracy Lynn ARAKAKI , Alex Buntin BURGIN , William Ross PITT , Mark Daniel CALMIANO , David Andreas SCHUBERT , Daniel John LIGHTWOOD , Rebecca Jayne MUNRO
- 申请人： UCB BIOPHARMA SRL
- 申请人地址： BE BRUSSELS
- 专利权人： UCB BIOPHARMA SRL
- 当前专利权人： UCB BIOPHARMA SRL
- 当前专利权人地址： BE BRUSSELS
- 优先权： GB1510758.4 20150618
- 主分类号： G01N33/68
- IPC分类号： G01N33/68 ; C07D401/14 ; C07K14/525 ; C07D471/00 ; C07K14/705 ; C07K16/24 ; C07D213/72 ; C07D235/04 ; C07D239/26 ; C07D471/04 ; A61K47/64 ; A61P37/00 ; A61P35/00
摘要：
A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.